Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 6/20 | 0.57 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.47 |
| ▸ | GGT1 | P19440 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.42 |
| ▸ | ITGAV | P06756 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6714094 | 1.00 | TLR2 (0.57) | TLR2FOLH1L3MBTL1GGT1SIGMAR1 | |
| SCHEMBL21122144 | 0.87 | FOLH1 (0.67) | TLR2FOLH1SIGMAR1 | |
| SCHEMBL21122143 | 0.87 | FOLH1 (0.67) | TLR2FOLH1SIGMAR1 | |
| SCHEMBL4576978 | 0.85 | TLR2 (0.60) | TLR2FOLH1GGT1POLBITGB3 | |
| Hydrochloric Acid SCHEMBL3229765 | 0.84 | TLR2 (0.65) | TLR2FOLH1POLB | |
| SCHEMBL30426128 | 0.84 | TLR2 (0.69) | TLR2FOLH1POLB | |
| SCHEMBL25380272 | 0.83 | TLR2 (0.61) | TLR2FOLH1GGT1POLB | |
| SCHEMBL3650068 | 0.82 | TLR2 (0.67) | TLR2FOLH1GGT1 | |
| SCHEMBL1976380 | 0.82 | TLR2 (0.67) | TLR2FOLH1GGT1 | |
| SCHEMBL8843364 | 0.81 | TLR2 (0.50) | TLR2FOLH1GGT1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545734-B2 | Chimeric antigen receptors that target molecules on disease-associated macrophages and methods related thererto, and treatment of fibrotic, inflammatory and autoimmune conditions | CELDARA MEDICAL LLC (US) | 2026-02-10 | — | — | US | disclosed |
| CN-112469446-A | Method for editing single nucleotide polymorphisms using a programmable base editor system | 比姆医疗股份有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20200369773-A1 | CELLULAR BASED THERAPIES TARGETING DISEASE-ASSOCIATED MOLECULAR MEDIATORS OF FIBROTIC, INFLAMMATORY AND AUTOIMMUNE CONDITIONS | THE TRUSTEES OF DARTMOUTH COLLEGE | 2020-11-26 | — | — | US | disclosed |
| EP-0832110-A1 | ANTIVIRAL PEPTOID COMPOUNDS | Novartis AG (CH) | 1998-04-01 | — | — | EP | disclosed |
| WO-1996040759-A1 | ANTIVIRAL PEPTOID COMPOUNDS | NOVARTIS AG (CH) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545734-B2 | Chimeric antigen receptors that target molecules on disease-associated macrophages and methods related thererto, and treatment of fibrotic, inflammatory and autoimmune conditions | CD40, TNFRSF9, CD74 | TLR2 242/4885FOLH1 1234/4885L3MBTL1 995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.